CoChat

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Open access
Klümper, Niklas, Ralser, Damian J., Ellinger, Jörg, Roghmann, Florian, Albrecht, Julia, Below, Eduard, Alajati, Abdullah, Sikic, Danijel, Breyer, Johannes, Bolenz, Christian, Zengerling, Friedemann, Erben, Philipp, Schwamborn, Kristina, Wirtz, Ralph M., Horn, Thomas, Nagy, Dora, Toma, Marieta, Kristiansen, Glen, Büttner, Thomas, Hahn, Oliver, Grünwald, Viktor, Darr, Christopher, Erne, Eva, Rausch, Steffen, Bedke, Jens, Schlack, Katrin, Abbas, Mahmoud, Zschäbitz, Stefanie, Schwab, Constantin, Mustea, Alexander, Adam, Patrick, Manseck, Andreas, Wullich, Bernd, Ritter, Manuel, Hartmann, Arndt, Gschwend, Jürgen, Weichert, Wilko, Erlmeier, Franziska, Hölzel, Michael, Eckstein, Markus · 2023 · Clinical Cancer Research
Cited by 227

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prevalence of membranous NECTIN-4 protein expression in primary tumors (PRIM) and patient-matched distant metastases (MET). Experimental Design: Membranous NECTIN-4 protein expression was measured (H-score) by IHC in PRIM and corresponding MET (N = 137) and in a multicenter EV-treated cohort (N = 47). Progression-free survival (PFS) after initiation of EV treatment was assessed for the NECTIN-4–negative/weak (H-score 0–99) versus moderate/strong (H-score 100–300) subgroup. The specificity of the NECTIN-4 IHC staining protocol was validated by establishing CRISPR-Cas9–induced polyclonal NECTIN-4 knockouts. Results: In our cohort, membranous NECTIN-4 expression significantly decreased during metastatic spread (Wilcoxon matched pairs P < 0.001; median H-score = 40; interquartile range, 0–140), with 39.4% of MET lacking membranous NECTIN-4 expression. In our multicenter EV cohort, absence or weak membranous NECTIN-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001). Conclusions: Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/progressive lesion) before initiation of EV. See related commentary by Aggen et al., p. 1377

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-1764

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 227

Metadata

Authors
Klümper, N., Ralser, D. J., Ellinger, J., Roghmann, F., Albrecht, J., Below, E., Alajati, A., Sikic, D., Breyer, J., Bolenz, C., Zengerling, F., Erben, P., Schwamborn, K., Wirtz, R. M., Horn, T., Nagy, D., Toma, M., Kristiansen, G., Büttner, T., Hahn, O., Grünwald, V., Darr, C., Erne, E., Rausch, S., Bedke, J., Schlack, K., Abbas, M., Zschäbitz, S., Schwab, C., Mustea, A., Adam, P., Manseck, A., Wullich, B., Ritter, M., Hartmann, A., Gschwend, J., Weichert, W., Erlmeier, F., Hölzel, M., & Eckstein, M.
Venue
Clinical Cancer Research
Published
2022-12-19
Volume
29
Issue
8
Pages
1496-1505
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4311928016
Cited by
227
References
3
FWCI
36.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-1764
The paper
Klümper, N., Ralser, D. J., Ellinger, J., Roghmann, F., Albrecht, J., Below, E., Alajati, A., Sikic, D., Breyer, J., Bolenz, C., Zengerling, F., Erben, P., Schwamborn, K., Wirtz, R. M., Horn, T., Nagy, D., Toma, M., Kristiansen, G., Büttner, T., . . . Eckstein, M. (2023). Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-1764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.